Business
Completion of Innovate UK Grant Project
Completion of Innovate UK Grant Project.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 3209H Physiomics PLC 12 March 2018 \n\n \n12th March 2018 \nPhysiomics plc \n(\"Physiomics\") or (\"the Company\")\n \nCompletion of Innovate UK Grant Project on Personalised Treatment of Oesophageal Cancer\n \nPhysiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry, is pleased to confirm that is has successfully completed the Innovate UK grant project announced in January 2017. The project was formally signed off by Innovate UK following a final project meeting in February this year. The Company can confirm that, in line with expectations, it received total funding of £131k from Innovate UK over the course of the project, of which around £81k will be recognised in the Company's current financial year.\nThe project \"Decision Support System For Stratified Cancer Treatment\" analysed data from over 400 oesophageal cancer patients to determine patient and disease specific factors that could help guide treatment to achieve the best outcomes, and created a tool for healthcare professionals to visualise this data. The project was conducted in collaboration with Prof Mark Middleton of Oxford University and the Oxford AHSN, and the Company intends to publicise the key results and findings of the project through an abstract, poster and other publications over the course of 2018 (further announcements will be forthcoming).\nThe results and learnings from the project have potential applications in both the Company's existing business advising R&D based pharmaceutical and biotech companies as well as in the emerging field of personalised cancer treatment. In order to further develop the technology the company is actively seeking additional grants in this space (as originally announced in October 2017).\nThe Company believes that the field of personalised or stratified cancer treatment, whether in R&D or in clinical practice will continue to gain importance in the short to medium term and that the Company is well positioned to contribute towards its development.\n \n \nEnquiries:\n \nPhysiomics plc &nbs...